Physician profile
Tari Smith
NPI 1073671038
$7,356.84
in general payments reported to CMS, 2019-2025
41 companies · $1,385 in 2025
The $1,385 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,107 · 2022: $1,406 · 2023: $1,655 · 2024: $1,804 · 2025: $1,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,844.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,148.60 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $976.18 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $672.70 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $589.11 | 2021-2025 | Jardiance |
| Abbvie INC. | $539.93 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $440.03 | 2021-2025 | Spravato, Xarelto |
| Astrazeneca Pharmaceuticals LP | $402.39 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbott Laboratories | $344.20 | 2022-2025 | Freestyle Libre 3, Diamondback Peripheral, Freestyle Libre 2 |
| Pfizer INC. | $300.21 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $223.84 | 2021-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.44 | 2021-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $197.26 | 2021-2025 | Arexvy, Shingrix |
| Dexcom, INC. | $150.35 | 2024-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $134.38 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $124.46 | 2024 | Voquezna |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $123.73 | 2022-2023 | Reveal Linq, Intellis Adaptivestim |
| Intra-Sana Laboratories | $77.99 | 2025 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Amgen INC. | $76.53 | 2025 | Otezla, Repatha, Krystexxa |
| Exact Sciences Corporation | $73.34 | 2023-2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $73.26 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $70.64 | 2022-2025 | |
| Phadia US INC. | $40.58 | 2022-2023 | Immunocap |
| Biohaven Pharmaceutical Holding Company LTD. | $37.10 | 2022 | |
| Astellas Pharma US INC | $36.91 | 2024 | Veozah |
| Biohaven Pharmaceuticals, INC. | $36.19 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $23.50 | 2025 | Rexulti |
| Electromed, INC. | $23.35 | 2025 | Smartvest |
| Mayne Pharma Commercial LLC | $23.26 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.70 | 2025 | Caplyta |
| Rgh Enterprises LLC | $17.76 | 2025 | |
| Aimmune Therapeutics, INC. | $17.44 | 2025 | Zenpep |
| Alnylam Pharmaceuticals INC. | $17.20 | 2021 | |
| Gilead Sciences, INC. | $16.05 | 2021 | |
| Cranial Technologies, INC | $14.95 | 2023 | Doc Band |
| Novavax INC | $14.82 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Vertex Pharmaceuticals Incorporated | $14.39 | 2025 | |
| Lnhc, INC | $14.32 | 2025 | Zelsuvmi |
| Grt US Holding, INC. | $13.98 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.41 | 2023 | Quviviq |
| Vbi Vaccine (Delaware) INC. | $11.05 | 2022 | |
| Janssen Biotech, INC. | $8.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tari Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.